Effects of co-treatment with mirtazapine and low doses of risperidone on immobility time in the forced swimming test in mice

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1191-1196

  Rogóz, Zofia ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Fluoxetine; Forced swimming test; Mice; Mirtazapine; Risperidone

Indexed keywords

FLUOXETINE; MIRTAZAPINE; RISPERIDONE; SEROTONIN 1A ANTAGONIST; UNCLASSIFIED DRUG; WAY 100636; YOHIMBINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN;

EID: 79551493931     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am, 1996, 19, 371-386.
2. Bschor T, Canata B, Muller-Oerlinghausen B, Bauer M: Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression. J Affect Disord, 2001, 64, 261-265.
3. Croom KF, Perry CM, Plosker GR: Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs, 2009, 23, 427-452.
4. Dhir A, Kulkarni SK: Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the mouse forced swim test. Pharmacology, 2007, 80, 239-243.
5. Dhir A, Kulkarni SK: Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neurosci Lett, 2008, 445, 83-88.
6. Dimitriou EC, Dimitriou CE: Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol, 1998, 18, 465-469.
7. Dremenkov E, Mansari EM, Blier P: Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol Psychiatry, 2007, 61, 671-678.
8. 2A receptor antagonistic activity. Neuropharmacology, 1996, 35, 1621-1626.
9. Hirose S, Ashby CR: An open pilot study combining risperidone and selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry, 2002, 63, 733-736.
10. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatry Res, 2009, 43, 205-214.
11. Korstein SG, Schneider RK: Clinical features of treatment-resistant depression. J Clin Psychiatry, 2001, 62, Suppl 16, 18-25.
12. Kumar R, Palit G, Dhawan BN: Comparative behavioral effects of typical and atypical antipsychotic drugs in rhesus monkey. Eur J Pharmacol, 2003, 462, 133-138.
13. Maes M, Vandoolaeghe E, Desnyder R: Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord, 1996, 41, 201-210.
14. Nierenberg AA, Amsterdam JD: Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry, 1990, 51, 39-47.
15. O'Connor M, Silver H: Additing risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol, 1998, 18, 89-91.
16. Ostroff RB, Nelson J: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry, 1999, 60, 256-259.
17. Porsolt RD, Bertin A, Jalfre M: Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther, 1977, 229, 327-336.
18. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I et al.: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 2006, 31, 2505-2513.
19. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 2000, 68, 29-39.
20. Rogóż Z: Potentiation of the antidepressant-like effect of desipramine or reboxetine by metyrapone in the forced swimming test in rats. Pharmacol Rep, 2009, 61, 1173-1178.
21. Salmerón JM, Alcántara AG, Barcia D: Combination of risperidone and serotonergic antidepressants in refractory obsessive-compulsive disorder. Actas Luco Esp Neurol Psiquiatr Cienc Afines (Spanish), 1998, 26, 399-402.
22. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 1996, 124, 57-73.
23. Shelton RC: Treatment options for refractory depression. J Clin Psychiatry, 1999, 60, Suppl 4, 57-61.
24. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antypsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand, 2008, 117, 253-259.
25. Skuza G, Rogóż Z: Antidepressant-like effect of PRE-084, a selective σ receptor agonist, in Albino Swiss and C57BL/6J mice. Pharmacol Rep, 2009, 61, 1179-1183.